Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-993 · 8 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| VX-993 | EXPERIMENTAL | Participants will be randomized to receive different dose levels of VX-993. |
| Hydrocodone bitartrate/acetaminophen (HB/APAP) | ACTIVE_COMPARATOR | Participants will be randomized to receive HB/APAP. |
| Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-993 and HB/APAP |
| Pregabalin | ACTIVE_COMPARATOR | Participants will be randomized to receive Pregabalin. |
| VX-993 and Metformin | EXPERIMENTAL | Metformin will be administered to participants as a single oral dose on Day 1 and then co-administered with VX-993 on Day 10. VX-993 dose will be administered every 12 hours (q12h) from Day 5 through Day 14. |
| Part A: Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-993. |
| Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A. |
| Placebo Part A | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-993. |
| Placebo Part B | PLACEBO_COMPARATOR | Participants will be randomized to receive multiple doses of placebo matched to VX-993. |
| Part A: Midazolam | EXPERIMENTAL | Participants will receive a single dose of Midazolam in absence and presence of VX-993. |
| Part B: Itraconazole | EXPERIMENTAL | Participants will receive a single dose of VX-993 on Day 1 and Itraconazole once daily (qd) on Days 7 through Day 15. On Day 10 participants will receive Itraconazole followed by VX-993. |
| Part C: Gemfibrozil | EXPERIMENTAL | Participants will receive a single dose of VX-993 on Day 1 and Gemfibrozil every 12 hours (q12d) on Days 7 through Day 15. On Day 10 participants will receive Gemfibrozil followed by VX-993. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-993. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo matched to VX-993. |
| Name | Type | Description |
|---|---|---|
| VX-993 | DRUG | Tablets for oral administration. |
| HB/APAP | DRUG | Capsules for oral administration. |
| Placebo (matched to VX-993) | DRUG | Placebo matched to VX-993 for oral administration. |
| Placebo (matched to HB/APAP) | DRUG | Placebo matched to HB/APAP for oral administration. |
| Pregabalin | DRUG | Capsules for oral administration. |
| Placebo (matched to pregabalin) | DRUG | Placebo matched to pregabalin for oral administration. |
| Metformin | DRUG | Tablets for Oral Administration. |
| Placebo | DRUG | Solution for IV administration. |
| Gemfibrozil | DRUG | Tablets for Oral Administration. |
| Itraconazole | DRUG | Capsules for Oral Administration. |
| Midazolam | DRUG | Solution for Oral Administration. |
Key Inclusion Criteria: Before Surgery: * Participant scheduled to undergo a primary unilateral bunionectomy with distal first metatarsal osteotomy (i.e., Austin procedure) and internal fixation under regional anesthesia (Mayo block) After Surgery: * Participant is lucid and able to follow comma...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
VX-993 is an investigational small molecule being developed by Vertex Pharmaceuticals for the treatment of pain, including diabetic peripheral neuropathic pain and acute pain. It is currently in Phase 2 clinical development.
VX-993 targets the NaV1.8 ion channel, a sodium channel involved in pain signaling. By modulating this channel, the drug aims to address pain conditions such as diabetic peripheral neuropathic pain and acute pain.
VX-993 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The drug is currently in Phase 2 clinical trials for pain indications.
VX-993 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of pain, including diabetic peripheral neuropathic pain and acute pain.
VX-993 has been studied in several clinical trials, including NCT05653323, a Phase 1 dose escalation study in healthy participants in the United Kingdom, and NCT06226454, a Phase 1 safety and pharmacokinetics study in the United States. Additional trials include NCT06392659 and NCT06508762, both Phase 1 studies.
VX-993 is a distinct investigational compound developed by Vertex Pharmaceuticals. No alternative names for VX-993 have been disclosed in clinical trial registrations. It is being studied specifically for pain conditions, including diabetic peripheral neuropathic pain and acute pain.